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Abstract: In recent years, the study of dermal preparations has received increased attention. There
are more and more modern approaches to evaluate transdermal formulations, which are crucial
in proving the efficacy of a formulation. The aim of this study was to compare permeation across
innovative synthetic membranes (Strat-M and Skin PAMPA membranes) and heat-separated human
epidermis (HSE, gold standard membrane) using four different dermal formulations. The Strat-M and
Skin PAMPA membranes were designed to mimic the stratum corneum layer of the human epidermis.
There have also been some publications on their use in dermal formulation development, but further
information is needed. Drug permeation was measured using formulations containing diclofenac
sodium (two hydrogels and two creams). The HSE, Strat-M, and Skin PAMPA membranes proved
to be significantly different, but based on the results, the Strat-M membrane showed the greatest
similarity to HSE. The permeation data of the different formulations across different membranes
showed good correlations with formulations similar to these four, which allows the prediction of
permeation across HSE using these synthetic membranes. In addition, Strat-M and Skin PAMPA
membranes have the potential to select and differentiate a dermal formulation containing diclofenac
sodium as an early screening model.
Keywords: Strat-M membrane; Skin PAMPA; heat-separated human epidermis; Franz diffusion
study; skin permeation
1. Introduction
The skin, the largest organ of the human body, provides an easily accessible surface
area for the possible administration of drugs, making it an attractive route for both topical
and systemic drug delivery. However, dermal drug delivery is a major challenge due to its
barrier function [1–3].
Numerous guidelines describe the possible test methods for modeling permeation
through the skin [4–8]. The most acceptable method for measuring in vitro skin permeation
is the use of the test formulation on the surface of the skin model, which is positioned
as a barrier between the donor compartment and the receptor compartment of the Franz
diffusion cell [9]. The benefits of the in vitro approach are that, in addition to other
alternative membranes, measurements can also be carried out on human skin samples.
Additional benefits are that several tests can be carried out on a skin sample from the same
donor and that many formulations can be tested at the same time.
In dermal permeation tests, human skin is considered a gold standard by regulatory
authorities [7]. Despite ethical concerns, human skin is widely used as a model in percu-
taneous absorption testing. Animal skin models are also utilized as convenient tools to
screen an extensive range of drugs, to assess skin permeation-enhancing processes, and to
measure the range of skin transport for variety of drug molecules. However, the usage of a
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broad number of animal and human skin models (e.g., permeation tests in excised animal
and human skin) in the scientific literature makes it complicated to appraise the valid
difference between the results obtained from various sources. Using biological membranes
has further disadvantages, which negatively affect the reliability of formulation screening
data. These properties include, for example, variations in skin thickness from skin donors,
diseased skin conditions, skin storage circumstances, membrane preparation complexity,
hair follicle density, donor age, and high laboratory costs [10,11]. In order to mimic human
skin, synthetic artificial membranes are engineered to offer a transparent and reproducible
alternative to human and animal skin. Synthetic membranes can easily be designed and
stored in contrast to biological membranes. The variability of drug delivery associated with
the use of biological skin is also minimized. Owing to their flexibility in deciding thickness,
inert nature, composition, ease of handling and storage, and reproducibility in the result of
permeation, artificial membranes can substitute human and animal skin models. These
advantages, along with ethical concerns, prompted scientists to find alternative ways to
minimize the usage of biological membranes in the initial phase of development [12–15].
There are many synthetic membranes available on the market. Most of these do not provide
relevant information compared to measurements on human skin. Typically, these only
function as filters with a certain pore size. Thus, in fact, the release of the active ingredient
from the formulation can only be measured. However, human skin studies show not only
the diffusion profile of the API, but possibly the interaction with the skin and the reservoir
function of the stratum corneum as well.
In order for suitable formulations to be placed on the market, studies are needed. The
most common measurement method is the use of different diffusion cells. In recent years,
there have been increasing efforts to produce membranes with properties similar to human
skin. In vitro permeation studies using well-defined skin models and membranes can be
useful tools in the design and optimization of skin formulations [12,13,16,17].
The Strat-M membrane has recently become commercially available. It is a special
synthetic model for predicting human skin permeation. As a synthetic test model with
low variability and no special storage or hydration requirements, the Strat-M membrane
simplifies experimental design and data analysis. Like human skin, the Strat-M membrane
has multiple layers with different diffuseness, including a very tight surface layer, which
is meant to imitate the stratum corneum layer of the human epidermis. The membrane
consists of two layers of polyethersulfone (more resistant to diffusion, like the stratum
corneum) on top of one layer of polyolefin (more open and diffuse, like deeper layers of the
skin). These polymeric layers form a porous structure with a gradient across the membrane
in terms of pore size and diffuseness [14,18–21].
The skin parallel artificial membrane permeability assay (Skin PAMPA) method is a
new type of skin permeation test. Skin PAMPA was created to imitate the characteristics
of the stratum corneum; for this purpose, the membrane is impregnated with cholesterol,
free fatty acid, and ceramide-analogue compounds [1,3,22]. Similarly to the other PAMPA
model, this technique is based on a sandwich of two 96-well microtiter plates fitting into
each other. The upper plate contains a PVDF filter (~membrane) with a pore size of
approximately 45 µm at its bottom [23], which is impregnated with the proper solution of
the components mentioned above. The advantage of this model is that it can be considered
a low-cost and high-throughput analysis. However, it should be noted that the applicability
of the synthetic membrane, in the case of formulation-containing penetration enhancers,
needs to be investigated in detail.
The aim of this study was to investigate the synthetic Strat-M and Skin PAMPA
membranes and compare them to heat-separated human epidermis. To achieve this, four
different formulations (two hydrogels and two creams) were examined. Diclofenac sodium
was incorporated in each formulation as API. We wanted to test how well the synthetic
membranes would statistically differentiate between various formulations and compare
these results to HSE data.
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2. Materials and Methods
2.1. Materials
Polysorbate 60 and propylene glycol were purchased from Sigma-Aldrich (Budapest,
Hungary). Methocel E4M (hydroxypropyl methylcellulose) was obtained from Colorcon
(Budapest, Hungary). Diclofenac sodium (DFNa), white beeswax, ethanol 96 w/w%, castor
oil, cetostearyl alcohol, white petrolatum, liquid paraffin, wool fat, and oleyl oleate were
purchased from Hungaropharma Ltd. (Budapest, Hungary). The water used was filtered
and deionized water was used (Millipore Milli-Q, Milford, MA, USA).
Excised human skin was collected from a Caucasian female patient who underwent
cosmetic abdominal surgery at the Albert Szent-Györgyi Clinical Center (Szeged, Hungary).
The technique of in vitro skin permeation does not require ethical approval or the consent
of the patient (Act CLIV of 1997 on Health, Section 210/A in Hungary). The Ethical
Committee of the University of Szeged was informed of the investigation. The human
investigation license code is 83/2008.
2.2. Methods
2.2.1. Sample Preparations
Hydrogel No1 (HG1) was formulated with Methocel E4M. It was added to one part of
propylene glycol. After waiting for 15 min, water was added to the gel in small amounts
under stirring. DFNa was dissolved in the other part of propylene glycol, and this was
added to the other part in small amounts under stirring.
Hydrogel No2 (HG2) was prepared in a mixture of purified water and ethanol 96 w/w%
with DFNa dissolved. Methocel E4M was added slowly and stirred until gelification.
The oily phase contains cetostearyl alcohol, liquid paraffin, white petrolatum, and
polysorbate 60 in the case of oil-in-water cream (O/W). This phase was heated to 60 ◦C
and hot purified water was emulsified into it under stirring. DFNα was added and
homogenized until cooled. In the case of water-in-oil cream (W/O), the oily phase contains
white beeswax, wool fat, oleyl oleate, and castor oil. After heating (60 ◦C), purified
water was emulsified in the oil phase under stirring. Finally, DFNα was added and
homogenized [24].
All formulations contained 1 w/w% of DFNa. The formulations are summarized in
the table below (Table 1).









Component % Component % Component % Component %
Diclofenac sodium 1 Diclofenac sodium 1 Diclofenac sodium 1 Diclofenac sodium 1
Methocel E4M 3 Methocel E4M 3 Cetostearyl alcohol 4 White beeswax 10
Propylene glycol 50 Ethanol 96 w/w% 30 Liquid paraffin 12 Wool fat 10
Purified water 46 Purified water 66 Polysorbate 60 4 Oleyl oleate 5
White Petrolatum 20 Castor oil 40
Purified water 59 Purified water 29
2.2.2. Preparation of Heat-Separated Epidermis
The heat-separation method was applied to isolate the epidermis [25]. The excised
human fat-free subcutaneous skin was put in a water bath (60 ± 0.5 ◦C, 1 min), and the
epidermis was separated from the dermis. In order to check the integrity, a visual inspection
was performed.
2.2.3. Franz Diffusion Cell Method
The in vitro permeation experiments were performed in a Logan Automated Dry Heat
Sampling System (Logan Instruments Corporation, Franklin Township, NJ, USA) with a
diffusion region of 1.77 cm2 and a receptor medium (PBS pH 7.4) capability of 9 mL. The
Franz cell system had thermostatic circulation at a steady temperature of 32 ± 0.5 ◦C, while
the receptor medium was continuously stirred at 500 rpm during the experiment. Strat-M
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membrane (Strat-M Membrane, Transdermal Diffusion Test Model, 25 mm, Merck KGaA,
Darmstadt, Germany) and HSE were used for the permeation tests as membranes. An
experiment was conducted for each measured membrane with six diffusion cells. Donor
compartments were open during the measurements, which better mimics the conditions
of application on real skin. Each membrane was carefully placed at the interface between
the donor and the receptor compartments. The amount of the formulation in the donor
compartment was about 300 mg. The examination lasted 12 h (sampling times: 0.5; 1; 2;
4; 6; 12 h). The amount of permeated drug was determined at a wavelength of 275 nm
with Thermo Scientific Evolution 201 spectrometer using Thermo Insight v1.4.40 software
package (Thermo Fisher Science, Waltham, MA, USA) [24]. Measurements were also
performed with each drug-free formulation. Data were corrected with the data of drug-free
formulations in all cases.
2.2.4. Skin PAMPA Method
The upper skin PAMPA plate (P/N: 120657, Pion, Inc, Woburn, MA, USA), was
impregnated with hydration solution (P/N: 120706, Pion, Inc., Billerica, MA, USA) for 24 h
before the tests. The donor phase was 70 µL of the preparations and the receptor phase was
phosphate buffer solution (PBS pH 7.4 ± 0.10). A total of 250 µL of receptor solution was
placed onto the upper plate, and the receptor medium was stirred and incubated at 32 ◦C
during the permeation (Gut-Box™ Pion, Inc., Billerica, MA, USA). The receptor solution
was analyzed after 0.5, 1, 2, 4, and 6 h of incubation [26]. The maximum length of the
permeation studies was 6 h because the decomposition of the membrane occurred in the
case of a longer test time. The permeated DFNa amount was analyzed by means of UV
spectroscopy at 275 nm using a SPECTROstarNano UV plate reader from BMG LABTECH
GmbH (Ortenberg, Germany).
2.2.5. Permeation Analysis
Permeation profiles were obtained for the four different formulations. The cumulated
DFNa quantity (Q, µg) permeated at 6 and 12 h was determined. The slope of the quan-
tities of permeated DFNa (µg/cm2) versus time (h) profiles was the flux (J). Timepoint
correlations were examined, and correlation coefficients (R2) were determined between the
quantities of DFNa permeated through the heat-separated human epidermis, the Strat-M,
and Skin PAMPA membrane.
2.2.6. Statistical Analysis
Data analysis, statistics, and graphs were performed from the experimental data with
Microsoft® Excel® (Microsoft Office Professional Plus 2013, Microsoft Excel 15.0.5023.100,
Microsoft Corporation, Washington, USA). Prism for Windows (GraphPad Software Inc.,
La Jolla, CA, USA) was used to conduct statistical data analysis using the one-way ANOVA
variance analysis (Tukey post hoc test). Differences were regarded as significant if * p < 0.05,
** p < 0.01 and *** p < 0.001 versus the control.
3. Results
Permeability is the ability of molecules to permeate through different layers of mem-
branes or skin. In our study, the biological HSE and the new special synthetic Strat-M and
Skin PAMPA membranes were compared with each other. The Strat-M, Skin PAMPA mem-
branes and HSE functioned as barriers to API permeation. The permeation of DFNa via the
Strat-M, skin PAMPA membranes, and HSE from different formulations is illustrated in
Figure 1. It can be clearly seen that the permeation profile of the formulation depends on
the applied membrane. In the case of HG1, the results of the Skin PAMPA membrane could
not be analyzed because the incompatibility of the membrane and polyethylene glycol was
observed during the penetration test. When HG1 and w/o formulations were applied, a
slow drug permeation could be seen, and the formulations showed a similar penetration
profile through HSE and Strat-M membrane.
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Figure 1. Permeation profile of different formulations using different membranes. Data represent mean and standard
deviation.
When applying alcoholic gel and o/w formulations, fast drug release was observed,
where the three different membranes meant different permeation rates during the in vitro
test. For both formulations, the fastest permeation was through the Skin PAMPA membrane
and the slowest through HSE. In the case of Franz cells, a larger concentration gradient can
be expected, as the ratio of donor to acceptor medium is 0.3:10. In contrast, in the case of
the PAMPA method, where there is a moderate difference between the two compartment
volumes, 70:250, an improved permeation could be observed, which can be explained by a
less complex membrane structure.
The linear regression of the permeation curves (Figure 1) resulted in a correlation
matrix, presented in Table 2, which indicated similar permeation profiles using different
in vitro membranes (Pearson r > 0.95). Based on these, the knowledge of the correlation
between membranes allows the interpretation of the assay on synthetic membranes for the
assay on HSE.
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HSE Strat-M Skin PAMPA
HSE - 0.9890 -
Strat-M 0.9890 - -
Skin PAMPA - - -
HG2
HSE Strat-M Skin PAMPA
HSE - 0.9970 0.9964
Strat-M 0.9970 - 0.9981
Skin PAMPA 0.9964 0.9981 -
O/W
HSE Strat-M Skin PAMPA
HSE - 0.9670 0.9956
Strat-M 0.9670 - 0.9521
Skin PAMPA 0.9956 0.9521 -
W/O
HSE Strat-M Skin PAMPA
HSE - 0.9993 0.99583
Strat-M 0.9993 - 0.9967
Skin PAMPA 0.9958 0.9967 -
Permeation values were plotted using a box plot. Box plots present the distribu-
tion of numerical data displaying the minimum and maximum data, the data quartiles
(or percentiles), and averages. When comparing the formulations, HG2 and o/w cream
showed the highest penetrated drug amount (Q), and rate (J) through the membranes
in vitro (Figures 2 and 3). These two formulations did not show any significant differences
concerning all analyzed permeation parameters (Q at 6 and 12 h, or J). This phenomenon
can be explained by different mechanisms, such as (1) the surfactant concentration of
the o/w emulsion can facilitate penetration through the membranes; (2) the supersatura-
tion of the evaporation alcoholic hydrogel (HG2) can force penetration; (3) solubility of
the API in the formulation; and (4) the complex cream structure can affect the drug diffu-
sion and permeation. The less-active ingredient permeated from the w/o cream and the
glycol-containing hydrogel (HG1). These two formulations presented similar permeation
parameters; no significant differences could be observed. HG1 contains propylene glycol,
which can improve the solubility of DFNa in the donor phase, while the complex cream
structure of the w/o cream can hinder the diffusion of the drug. These two phenomena
can lead to lower penetration. Donor compartments of the Franz cells were open during
the measurements, which better mimics the conditions of application to real skin. The
alcoholic gel (HG2) continuously evaporates during the measurements, which leads to an
increase in the concentration of the donor phase, so that the evaporation of the propylene
glycol-containing gel (HG1) is minimal due to the hygroscopicity of the propylene glycol.
An increase in the drug concentration in the donor phase may increase penetration, as
indicated by better penetration from the alcohol gel in our results in the case of Franz
cell measurements.
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4. Discussion
In our study, Strat-M and Skin PAMPA membranes were applied as synthetic mem-
branes and compared with each other and with HSE.
The Strat-M membrane is composed of multiple layers (stratum corneum, dermis,
and subcutaneous tissue mimicking layers) of the membrane, which is similar in structure
to human skin. We already have some information about permeation across the Strat-M
membrane correlating well with that through human skin [14,15,21] as well as animal
skin [27]. In addition, the Strat-M membrane has low batch-to-batch variability, is easy
to use, and does not need special storage conditions [28]. In our study, we demonstrated
that the permeation profile across the Strat-M membrane was similar to HSE (Table 2), but
the general permeation data (Q and J) were significantly higher (p < 0.05) (Figure 3) in the
case of the Strat-M membrane. The only exception was the w/o formulation, where no
significant differences were found. A similar finding was described by Nair et al., namely
that the flux value of tocotrienol ethosomes permeation across the Strat-M was significantly
higher than that across full-thickness human skin (p < 0.05) [29].
The Skin PAMPA membrane is a completely artificial membrane, mimicking perme-
ation through the stratum corneum. It was designed to predict transdermal permeation in a
quick, reliable, and cost-effective way [22]. The Skin PAMPA can be used for semisolids [24]
and patch formulations [30] as well; it was found to correlate with ex vivo permeation stud-
ies [31]. The shortcoming of the Skin PAMPA membrane is that it does not represent the
biological complexity of skin, and it does not contain, e.g., proteins, corneocytes, and special
lipid subclasses of human skin [32,33]. There are some limitations concerning test length
and the applicable material during the PAMPA test because different additives can change
the permeability of the membrane. Some information is available about the compatibility
of the Skin PAMPA membrane with lipophilic solvents/penetration enhancers, organic
acceptor media additives such as isopropyl myristate, dimethyl isosorbide, propylene
glycol, diisopropyl adipate, DMSO, and ethanol in the case of the 4 h test length [33], but it
is strongly advisable to check the compatibility between the components/media and the
membrane at the beginning of the tests. In our case, propylene glycol was applied in HG1
formulation, but during the 6 h test period, presumably due to incompatibility with the
membrane, evaluable data were not obtained during the test. Although the purpose of our
article was not to investigate possible incompatibilities, it may be important information
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for comparing the applicability of synthetic membranes. In our work, the permeation
profile across Skin PAMPA was similar to that through HSE (Table 2), but the permeation
data (Q and J) were significantly different from HSE (Figure 3).
The permeation of different topical formulations (gels and creams) was analyzed
across synthetic membranes and HSE; therefore, our statistical analysis allowed the com-
parison of synthetic membranes with each other and with HSE as well. We found that
the permeation profile was similar in each comparison (see correlation matrix in Table 2).
Differences can be evaluated in terms of statistical differences. In the case of HSE, in
addition to the relatively small permeation, large standard deviations could be observed,
which makes it difficult to detect statistically significant differences, so the differences dis-
appear. In contrast, the small standard deviation of the values measured on the synthetic
membranes allows a statistical interpretation of the differences. A general order could also
be established for permeation data of Q and J: the highest values could be measured for
Skin PAMPA, and the lowest values for HSE (Figure 3).
It is important that Strat-M and Skin PAMPA will only provide information on trends
and correlations and cannot match absolute permeability values for human skin in every
preparation. The permeation efficiency rating helps to identify which methods are the
most efficient in developing and optimizing formulations. However, this information can
be used to select medications or permeation enhancers or medication/active vehicles in
preliminary screening procedures in the pharmaceutical, cosmetic, and personal care in-
dustries. Furthermore, skin-mimicking synthetic membranes may be a convenient method
for studying and testing the most effective permeation for human skin to be used in vivo.
The Strat-M and Skin PAMPA synthetic membranes are quick, cost-effective, easy-to-use,
and ready-to-use systems. They can also be used effectively to select the most suitable
preparations and to monitor dermal formulations across the human skin as a screening
technique. In the pharmaceutical and cosmetic industries, the investigated synthetic mem-
branes could be seen as a cheaper alternative for screening topical formulations and active
ingredients. However, their applicability in the case of penetration enhancers needs to be
assessed separately.
In this study, the Strat-M membrane seems to have a stronger association in permeation
data relative to human skin, indicating its validity as a substitute for human skin, and, in
addition, it also makes it possible to present differences in composition during the early
development phase.
5. Conclusions
In conclusion, this study has shown that Strat-M and Skin PAMPA synthetic mem-
branes have a large correlation with HSE and have the potential to select and differentiate
a dermal formulation containing diclofenac sodium as an early screening model. However,
it should be noted that when using penetration enhancers, special consideration should
be given to evaluating the penetration-enhancing effect during the selection of the appro-
priate membrane. Although more research is needed on complex topical formulations,
these results suggest potential use as an initial screening technique to help the selection
of formulations to be studied using a more biologically intact model, thereby helping to
develop new topical formulations.
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